Durect Corp (NAS:DRRX)
$ 0.95 -0.0181 (-1.87%) Market Cap: 29.49 Mil Enterprise Value: 32.85 Mil PE Ratio: 0 PB Ratio: 24.36 GF Score: 56/100

DURECT Corporation - Special Call Transcript

Feb 02, 2021 / 09:30PM GMT
Release Date Price: $24.8 (+18.10%)
Operator

Greetings, and welcome to the DURECT Corporation conference call. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Mike Arenberg, Chief Financial Officer. Please go ahead.

Michael H. Arenberg
DURECT Corporation - CFO & Secretary

Good afternoon, and welcome to our conference call to discuss the POSIMIR approval. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.

Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding POSIMIR as well as DURECT's products in development, expected product benefits, regulatory and partnering strategies, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot